Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

This study tests a combination of chidamide (an epigenetic drug) and AK112 (a dual immunotherapy drug) for people with advanced bone and soft tissue sarcomas that stopped responding to first-line treatment. It includes many types of sarcoma such as synovial sarcoma, osteosarcoma, rhabdomyosarcoma, and others. **You may be eligible if...** - You are 18–75 years old with an advanced bone or soft tissue sarcoma confirmed by biopsy - Your cancer progressed during or after first-line standard treatment - You have at least one measurable tumor - Your general health score is 0–1 (ECOG) and expected survival is more than 3 months - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - You have certain excluded types of sarcoma (e.g., mesothelioma, gastrointestinal stromal tumor, alveolar soft tissue sarcoma, extra-osseous myxoid chondrosarcoma) - You have active brain metastases - You have received prior treatment with similar immunotherapy or epigenetic drugs - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.